Both MyoKardia Inc. (NASDAQ:MYOK) and Molecular Templates Inc. (NASDAQ:MTEM) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MyoKardia Inc.	33.56M	67.12	67.70M	-1.59	0.00
Molecular Templates Inc.	13.29M	17.56	30.29M	-1.13	0.00

Table 1 shows the gross revenue, earnings per share and valuation for MyoKardia Inc. and Molecular Templates Inc.

Profitability

Table 2 provides us MyoKardia Inc. and Molecular Templates Inc.’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
MyoKardia Inc.	-201.73%	-19.9%	-17.2%
Molecular Templates Inc.	-227.92%	-38.6%	-29.9%

Volatility and Risk

MyoKardia Inc. has a 2.42 beta, while its volatility is 142.00% which is more volatile than Standard and Poor’s 500. From a competition point of view, Molecular Templates Inc. has a 3.09 beta which is 209.00% more volatile compared to Standard and Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of MyoKardia Inc. are 8.6 and 8.6 respectively. Its competitor Molecular Templates Inc.’s Current Ratio is 2.8 and its Quick Ratio is 2.8. MyoKardia Inc. can pay off short and long-term obligations better than Molecular Templates Inc.

Analyst Ratings

The Recommendations and Ratings for MyoKardia Inc. and Molecular Templates Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
MyoKardia Inc.	0	0	1	3.00
Molecular Templates Inc.	0	0	0	0.00

MyoKardia Inc.’s average target price is $85, while its potential upside is 70.75%.

Insider & Institutional Ownership

Institutional investors owned 92.4% of MyoKardia Inc. shares and 73% of Molecular Templates Inc. shares. About 0.6% of MyoKardia Inc.’s share are owned by insiders. Comparatively, Molecular Templates Inc. has 0.7% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
MyoKardia Inc.	14.82%	23.78%	-14.83%	-13.92%	-14.35%	4.83%
Molecular Templates Inc.	-9.52%	0.21%	-1.25%	-13.64%	-47.97%	17.57%

For the past year MyoKardia Inc. has weaker performance than Molecular Templates Inc.

Summary

On 8 of the 11 factors MyoKardia Inc. beats Molecular Templates Inc.

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). The company also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart. In addition, it develops HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, a product candidate that is intended to increase cardiac muscle contractility to normal levels in genetic DCM patients through a different mechanism than that of MYK-491; and LUS-1, a product candidate, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart. The company has a strategic collaboration with Sanofi S.A. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.